Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
Revive Therapeutics (OTCQB: RVVTF) announced an update on their research study evaluating Bucillamine as a potential treatment for nerve agent exposure, conducted in partnership with Defence R&D Canada – Suffield Research Centre. The study is progressing with final results expected by end of 2024. If promising, results will determine further studies for FDA and Health Canada approvals for nerve agent and organophosphate pesticide poisoning treatments. Bucillamine, being a more effective antioxidant than n-acetylcysteine (NAC), could potentially provide increased efficacy against seizure activity while reducing anticoagulant and bleeding risks associated with NAC.
Revive Therapeutics (OTCQB: RVVTF) ha annunciato un aggiornamento sulla loro ricerca che valuta Bucillamine come potenziale trattamento per l'esposizione agli agenti nervini, condotta in collaborazione con il Defence R&D Canada – Suffield Research Centre. Lo studio sta progredendo e i risultati finali sono attesi entro la fine del 2024. Se i risultati saranno promettenti, essi determineranno ulteriori studi per le approvazioni della FDA e di Health Canada per i trattamenti contro l'avvelenamento da agenti nervini e pesticidi organofosforici. La Bucillamine, essendo un antiossidante più efficace rispetto all'n-acetilcisteina (NAC), potrebbe potenzialmente fornire una maggiore efficacia contro l'attività convulsiva, riducendo al contempo i rischi di anticoagulazione e sanguinamento associati al NAC.
Revive Therapeutics (OTCQB: RVVTF) anunció una actualización sobre su estudio de investigación que evalúa Bucillamine como un posible tratamiento para la exposición a agentes nerviosos, llevado a cabo en colaboración con Defence R&D Canada – Suffield Research Centre. El estudio avanza y se esperan resultados finales para finales de 2024. Si los resultados son prometedores, determinarán más estudios para las aprobaciones de la FDA y de Health Canada para tratamientos contra el envenenamiento por agentes nerviosos y pesticidas organofosforados. La Bucillamine, siendo un antioxidante más eficaz que la n-acetilcisteína (NAC), podría proporcionar potencialmente una mayor eficacia contra la actividad convulsiva, al tiempo que reduce los riesgos de anticoagulantes y sangrado asociados con NAC.
Revive Therapeutics (OTCQB: RVVTF)는 신경 작용제 노출에 대한 잠재적 치료제로 Bucillamine을 평가하는 연구의 업데이트를 발표했습니다. 이 연구는 Defence R&D Canada – Suffield Research Centre와 협력하여 진행되고 있습니다. 연구는 순조롭게 진행 중이며 최종 결과는 2024년 말에 기대되고 있습니다. 만약 결과가 유망하다면, 이 결과는 신경 작용제 및 유기인 살충제 중독 치료를 위한 FDA 및 Health Canada의 승인을 위한 추가 연구를 결정할 것입니다. Bucillamine은 n-아세틸시스테인(NAC)보다 더 효과적인 항산화제가 되어, 발작 활동에 대해 더 높은 효능을 제공하면서 NAC와 관련된 항응고제 및 출혈 위험을 줄일 수 있습니다.
Revive Therapeutics (OTCQB: RVVTF) a annoncé une mise à jour sur leur étude de recherche évaluant Bucillamine en tant que traitement potentiel de l'exposition aux agents neurotoxiques, réalisée en partenariat avec Defence R&D Canada – Suffield Research Centre. L'étude progresse et les résultats finaux sont attendus d'ici fin 2024. Si les résultats s'avèrent prometteurs, ceux-ci détermineront d'autres études pour les approbations de la FDA et de Santé Canada concernant les traitements des intoxications aux agents neurotoxiques et aux pesticides organophosphorés. La Bucillamine, étant un antioxydant plus efficace que la n-acétylcystéine (NAC), pourrait potentiellement offrir une plus grande efficacité contre l'activité convulsive tout en réduisant les risques d'anticoagulants et de saignements associés à la NAC.
Revive Therapeutics (OTCQB: RVVTF) hat ein Update zu ihrer Forschungsstudie veröffentlicht, in der Bucillamine als potenzielle Behandlung für die Exposition gegenüber Nervengiften evaluiert wird. Diese Studie wird in Zusammenarbeit mit Defence R&D Canada – Suffield Research Centre durchgeführt. Die Studie schreitet voran, wobei die finalen Ergebnisse bis Ende 2024 erwartet werden. Sollten die Ergebnisse vielversprechend sein, werden sie weitere Studien zur Genehmigung durch die FDA und Health Canada für Behandlungen gegen Nervengift- und Organophosphat-Pestizidvergiftungen bestimmen. Bucillamine, welches ein effektiveres Antioxidans als n-Acetylcystein (NAC) ist, könnte möglicherweise eine höhere Wirksamkeit gegen Krampfaktivität bieten und gleichzeitig die Risiken von Antikoagulanzien und Blutungen, die mit NAC verbunden sind, verringern.
- Research study progressing with final results expected by end of 2024
- Bucillamine shows potential advantages over existing NAC treatment with better antioxidant properties
- Potential for multiple treatment applications including nerve agents, pesticide poisoning, and traumatic brain injury
- None.
TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury.
The DRDC conducted an additional control study to achieve optimal dosing. The research study is progressing and is now expected to be completed with final results by the end of calendar 2024. The results from this research study, if promising, will determine further studies to facilitate FDA and Health Canada approvals for the use of Bucillamine in nerve agents or organophosphate pesticide poisoning and explore its potential for traumatic brain injury caused by concussive or explosive forces and viral infections.
Nerve agents are chemicals that affect the nervous system. Nerve agents are highly toxic regardless of the route of exposure. The main chemical nerve agents that are man-made and manufactured for use in chemical warfare are sarin, soman, tabun and VX. These nerve agents are known to be present in military stockpiles. Exposure to nerve agents can occur due to chemical warfare or accidental release from a military storage facility. Exposure to nerve agents can cause tightness of the chest, excessive salivation, abdominal cramps, diarrhea, blurred vision, tremors, and death.
Recent studies have shown that antioxidant compounds such as n-acetylcysteine (“NAC”) could be beneficial in limiting seizure activity and improving the anticonvulsant efficacy of GABA-mediating drugs such as diazepam.
Bucillamine is a significantly more effective antioxidant than NAC and has the potential to provide increased efficacy against seizure activity while limiting the anticoagulant and bleeding event liability observed with NAC. The overall objective of the research project is to investigate pharmacological means for neuroprotection of GABA(A) receptors, which are required for the effectiveness of currently fielded anticonvulsant therapies. Bucillamine and NAC will be evaluated to determine the effect on GABA(A) receptor endocytosis and the effect on diazepam effectiveness in terminating seizures. Any additional antioxidant effects on seizure activity and survival will also be assessed.
About Revive Therapeutics Ltd.
Revive Therapeutics is a life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. Revive prioritizes its drug development efforts to take advantage of several regulatory incentives awarded by the FDA, such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. Revive is also advancing the development of Psilocybin-based therapeutics through various programs. For more information, visit www.ReviveThera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “may”, “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company’s cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company's management's discussion and analysis for the year ended June 30, 2024 ("MD&A"), dated October 25, 2024, which is available on the Company's profile at www.sedarplus.ca.
FAQ
When will Revive Therapeutics (RVVTF) complete its Bucillamine nerve agent exposure study?
What advantages does Bucillamine have over NAC in Revive Therapeutics' (RVVTF) nerve agent study?
What potential applications is Revive Therapeutics (RVVTF) exploring for Bucillamine?
